Colin Carrie on Questions Passed as Orders for Returns

With regard to Health Canada’s (HC) authorization of the Pfizer, Moderna, and AstraZeneca COVID-19 vaccines: (a) how much of the vaccine components (lipid nanoparticles, modified RNA) and its derivative spike protein do peoples’ bodies make after their injection of Pfizer, Moderna or AstraZeneca COVID-19 vaccines, (i) do different people make different amounts, (ii) in what bodily organs, tissues or systems, including breast milk, is the spike protein, lipid nanoparticles and modified RNA found after an injection, (iii) is there a blood test to detect the spike protein, (iv) is there a blood test readily available to Canadians, particularly those who have been vaccine-injured or for those with symptoms of long COVID, (v) how long can spike protein be found in the body post-injection; (b) at the time of release of the mRNA products, were genotoxicity, reproductive and carcinogenicity analyses completed; (c) if the answer to (b) is affirmative, (i) who completed these studies, (ii) were studies conducted on females and males, (iii) how long were the sires, dams and offspring followed in the studies, (iv) what methods were used to assess potential harms, (v) what species of animals were used in the studies, (vi) do the animals express high or low affinity ACE2 receptor; and (d) if the answer to (b) is negative, has HC, the Public Health Agency of Canada, or the National Advisory Committee requested these studies from the manufacturers or from independent researchers, and, if not, when might these studies be (i) completed, (ii) released, and by whom?